The role of VEGF in melanoma progression

Journal of Research in Medical Sciences

Volumn 17, Issue 6, 2012, Pages 534-539

  Rajabi, Parvin ^a   Neshat, Al ^a   Mokhtari, Mozhgan ^a   Rajabi, Mohammad A ^a   Eftekhari Dr , Mehdi ^a   Tavakkoli, Payam ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breslow's depth; Melanoma; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GROWTH CURVE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; TUMOR GROWTH;

EID: 84865563248     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J Am Acad Dermatol 1996;34:839-47.
2. Berwick M, Wiggins C. The current epidemiology of cutaneous malignant melanoma. Front Biosci 2006;11:1244-54.
3. Liu V, Mihm MC. Pathology of malignant melanoma. Surg Clin North Am 2003;83:31-60, v.
4. Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: Prognostic factors. Cancer Control 2005;12:223-9.
5. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-51.
6. Heenen M, Laporte M. [Molecular markers associated to prognosis of melanoma]. Ann Dermatol Venereol 2003;130:1025-31.
7. Gallagher PG, Bao Y, Prorock A, Zigrino P, Nischt R, Politi V, et al. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: Implications for host-tumor interactions in metastasis. Cancer Res 2005;65:4134-46.
8. Miller KD. Recent translational research: Antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Res 2004;6:128-32.
9. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994;5:89-97.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
11. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: A new frontier of metastasis research. Nat Cell Biol 2002;4:E2-5.
12. Gitay-Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993;190:702-8.
13. Bayer-Garner IB, Hough AJ Jr, Smoller BR. Vascular endothelial growth factor expression in malignant melanoma: Prognostic versus diagnostic usefulness. Mod Pathol. 1999 Aug;12(8):770-4.
14. Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159:223-35.
15. Depasquale I, Thompson WD. Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. Histopathology 2008;52:500-9.
16. Chua R, Setzer S, Govindarajan B, Sexton D, Cohen C, Arbiser JL. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol 2009;60:758-66.
17. Ballaun C, Weninger W, Uthman A, Weich H, Tschachler E. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 1995;104:7-10.
18. Nor JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154:375-84.
19. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999;264:781-8.
20. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001;61:2183-8.
21. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol 2008;25:431-6.
22. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895-8.
23. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ, et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 1995 12;270:11322-6.
24. Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995;217:721-7.
25. Herold-Mende C, Steiner HH, Andl T, Riede D, Buttler A, Reisser C, et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 1999;79:1573-82.
26. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-81.
27. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
28. Burbridge MF, Coge F, Galizzi JP, Boutin JA, West DC, Tucker GC. The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis 2002;5:215-26.
29. Srivastava A, Ralhan R, Kaur J. Angiogenesis in cutaneous melanoma: Pathogenesis and clinical implications. Microsc Res Tech 2003;60:208-24.
30. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 2005;62:1021-32.
31. Gille J. Antiangiogenic cancer therapies get their act together: Current developments and future prospects of growth factor-and growth factor receptor-targeted approaches. Exp Dermatol 2006;15:175-86.
32. Redondo P, Bandres E, Solano T, Okroujnov I, Garcia-Foncillas J. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine 2000;12:374-8.
33. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-83.
34. Redondo P, Sanchez-Carpintero I, Bauza A, Idoate M, Solano T, Mihm MC, Jr. Immunologic escape and angiogenesis in human malignant melanoma. J Am Acad Dermatol 2003;49:255-63.
35. Viac J, Schmitt D, Claudy A. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett 1998;125:35-8.
36. Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol 2005;152:685-9.
37. Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel- Lewandrowski C, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007;110:2519-27.
38. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997;7 Suppl 2:S19-26.
39. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997;76:930-4.
40. Marcoval J, Moreno A, Graells J, Vidal A, Escriba JM, Garcia-Ramirez M, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 1997;24:212-8.
41. Graeven U, Fiedler W, Karpinski S, Ergun S, Kilic N, Rodeck U, et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol 1999;125:621-9.
42. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000;115:1000-7.
43. Pisacane AM, Risio M. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res 2005;15:39-43.
44. Frohlich E, Mack AF, Garbe C, Klessen C. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas. Br J Dermatol 2005;153:1159-65.
45. Brychtova S, Bezdekova M, Brychta T, Tichy M. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 2008;55:273-9.
46. Gajanin V, Krivokuca Z, Kostic K, Gajanin R, Sladojevic I. Significance of vascular endothelial growth factor expression in skin melanoma. Vojnosanit Pregl 2010;67:747-54.